Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710250 | 0.93 | KMT2A (0.42) | KMT2ANPC1RAB9ANR1H4MEN1 | |
| SCHEMBL6708817 | 0.93 | IRAK4 (0.40) | TDP1GPR35NR1H4RXFP1HIF1A | |
| SCHEMBL6709197 | 0.92 | IRAK4 (0.42) | KMT2ANPC1RAB9ANR1H4MEN1 | |
| SCHEMBL6707952 | 0.91 | PRSS12 (0.39) | KMT2ANPC1RAB9ANR1H4MEN1 | |
| SCHEMBL6713465 | 0.90 | GPR35 (0.43) | TDP1GPR35RXFP1HIF1ANPSR1 | |
| SCHEMBL6713373 | 0.90 | RXFP1 (0.40) | GPR35KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL6710380 | 0.90 | MAP3K5 (0.43) | TDP1KMT2ANPC1RAB9ANR1H4 | |
| SCHEMBL6710254 | 0.89 | NPC1 (0.40) | NPC1RAB9A | |
| SCHEMBL6711773 | 0.88 | KMT2A (0.48) | KMT2AMEN1 | |
| SCHEMBL6709018 | 0.87 | PKM (0.35) | TDP1RXFP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | TDP1 2977/4885GPR35 2928/4885KMT2A 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.